Others have demonstrated the use of sapanisertib in clinical trials in conjugation with metformin, a widely used drug for treating T2D that also exhibits mTOR inhibitory functions, which could further enhance the antitumor effects, preventing cancer progression [43,44,45,46]. This evidence concerns the gene MTOR and cancer.